SCHEMBL308119

SCHEMBL308119

CCCC(CCC)CCCCCO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
ALDH1A1 P00352 3/20 0.52
TSHR P16473 2/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.48
CYP2D6 P10635 2/20 0.35
SPHK1 Q9NYA1 1/20 0.35
GMNN O75496 1/20 0.35
POLB P06746 1/20 0.35
THPO P40225 1/20 0.35
MTOR P42345 1/20 0.35
BLM P54132 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CETP P11597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099125 0.97 LMNA (0.50) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL6440890 0.97 LMNA (0.50) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL7208155 0.95 LMNA (0.62) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL3088613 0.95 LMNA (0.62) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL4920668 0.95 LMNA (0.62) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL3090810 0.95 LMNA (0.62) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL6440790 0.95 LMNA (0.56) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL3098238 0.95 LMNA (0.62) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL1433752 0.95 LMNA (0.48) LMNAALDH1A1TSHRHSD17B10MEN1
SCHEMBL8997997 0.92 LMNA (0.46) LMNAALDH1A1TSHRHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981859-B1 PREPARATION OF DELMOPINOL SINCLAIR PHARMACEUTICALS LTD (GB) 2012-10-31 EP disclosed
EP-1981859-B1 PREPARATION OF DELMOPINOL SINCLAIR PHARMACEUTICALS LTD (GB) 2012-10-31 EP disclosed
US-8093398-B2 Preparation of delmopinol Sinclair Pharmaceticals Limited (GB) 2012-01-10 US disclosed
US-8093398-B2 Preparation of delmopinol Sinclair Pharmaceticals Limited (GB) 2012-01-10 US disclosed
US-8093398-B2 Preparation of delmopinol Sinclair Pharmaceticals Limited (GB) 2012-01-10 US disclosed
US-20110082301-A1 Preparation of Delmopinol COMELY ALEXANDER 2011-04-07 US disclosed
US-20110082301-A1 Preparation of Delmopinol COMELY ALEXANDER 2011-04-07 US disclosed
US-20110082301-A1 Preparation of Delmopinol COMELY ALEXANDER 2011-04-07 US disclosed
US-7893258-B2 Preparation of delmopinol SINCLAIR PHARMACEUTICALS LIMITED (GB) 2011-02-22 US disclosed
US-7893258-B2 Preparation of delmopinol SINCLAIR PHARMACEUTICALS LIMITED (GB) 2011-02-22 US disclosed
US-7893258-B2 Preparation of delmopinol SINCLAIR PHARMACEUTICALS LIMITED (GB) 2011-02-22 US disclosed
US-20090036677-A1 Preparation of Delmopinol MAELOR LABORATORIES LIMITED (GB) 2009-02-05 US disclosed
US-20090036677-A1 Preparation of Delmopinol MAELOR LABORATORIES LIMITED (GB) 2009-02-05 US disclosed
US-20090036677-A1 Preparation of Delmopinol MAELOR LABORATORIES LIMITED (GB) 2009-02-05 US disclosed
EP-1981859-A2 PREPARATION OF DELMOPINOL Sinclair Pharmaceuticals Limited (GB) 2008-10-22 EP disclosed
WO-2007091009-A2 PREPARATION OF DELMOPINOL SINCLAIR PHARMACEUTICALS LIMITED (GB) 2007-08-16 WO disclosed
WO-2007091009-A2 PREPARATION OF DELMOPINOL SINCLAIR PHARMACEUTICALS LIMITED (GB) 2007-08-16 WO disclosed
US-6888030-B2 Advances in amination HUNTSMAN PETROCHEMICAL CORPORATION (US) 2005-05-03 US disclosed
US-20030078344-A1 Advances in amination HUNTSMAN PETROCHEMICAL CORPORATION 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082301-A1 Preparation of Delmopinol CBR3, AVPR2, C1S LMNA 1431/4885ALDH1A1 2640/4885TSHR 466/4885
US-20090036677-A1 Preparation of Delmopinol AVPR2, CBR3, C1S LMNA 1203/4885ALDH1A1 2718/4885TSHR 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.